HaHa!! KNDI is Junk right now. I first bought it at 11ish and sold at 19.00 when it went to 22.00 I have traded it quite a bit when it gets oversold but other than that I don't hold a position. The shorts own it. The company may be legit but if I did buy it again it would be a pure spec. The company is very secretive and shady in my opinion. Good Luck..........Beegz.
Yeah, Not much intelligent MNK information talked about around here anymore. One BIG food fight. Vroooooom!! Good Luck!! Beegz.
Perrigo Company plc (NYSE: PRGO) announced it has received final U.S. Food and Drug Administration ("FDA") approval for the generic version of Mallinckrodt Pharmaceuticals' (NYSE: MNK) Ofirmev (acetaminophen) injection 1000 mg/100 mL.
As previously announced, Perrigo can launch a generic version of Ofirmev® (acetaminophen) injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Mallinckrodt elect to launch an authorized generic product.
Ofirmev® (acetaminophen) injection 1000 mg/100 mL is indicated for the management of mild to moderate pain, management of moderate to severe pain with adjunctive opioid analgesics, and reduction of fever. Branded sales for the twelve months ending April 2016 were $275 million.
Perrigo's CEO John T. Hendrickson stated, "This product approval demonstrates the strength of Perrigo's Rx portfolio. Approvals in difficult formulations like this are what drive Perrigo's diverse product portfolio, which continues to provide a unique offering to our customers around the world.
Received this today via Google Scholar. Just more of what we already knew:
Background: Treatment of multiple sclerosis (MS) relapses can be complex in patients with concomitant diabetes. Corticosteroids and adrenocorticotropic hormones are known to cause alterations in glucose tolerance. Many patients have poor tolerability to therapy, necessitating alternative treatment options. Adrenocorticotropic hormone (H.P. Acthar Gel, repository corticotropin injection, Mallinckrodt ARD Inc., Hazelwood, MO, USA) is currently indicated for the treatment of MS relapses.
Objectives: The objective of this study was to review patients’ experiences of Acthar Gel for the treatment of MS exacerbations in patients with MS and diabetes.
Methods: A retrospective review of 13 patients’ experiences with treatment. Qualified healthcare providers completed a questionnaire following Acthar Gel treatment for MS relapse.
Results: Previous corticosteroid treatment with either intravenous methylprednisolone or prednisone was reported by 84.6% of patients; eight patients had complications following administration of prior steroid treatment, seven of whom experienced elevated blood glucose levels. Acthar Gel was administered daily for a mean of 5.3 days, with 61.5% of patients reporting relapse resolution. Two patients experienced elevated blood glucose.
Conclusion: The majority of patients experienced a timely resolution of their MS relapse with few hyperglycemic adverse events. Although more studies are necessary, these data suggest that Acthar Gel may be a well-tolerated and effective treatment option for patients with diabetes experiencing an MS relapse.
Source: Sage Journals Chronic Disease. Beegz
They just had a CC 2 weeks ago where they updated shareholders. What do you want.
According to Bloomberg, Yesterday, the Supreme Court ruled that Financial Institutions that facilitate Naked Short selling may now be sued in State Courts rather than Federal Courts. In NJ they can be sued under the RICO statute. Case now pending against BAML. Well see what happens. Probably not much. Beegz
Recently published Abstract on Acthar for Migraines. Sorry if this has already been posted.
Objective: The goal of this study was to examine the effects of ACTH gel in chronic migraine patients who had failed multiple preventative treatments. Background: Despite the availability of many therapies for migraine prevention, there remain a significant number of patients whose migraines are refractory to treatment. Adrenocorticotropic hormone (ACTH) causes the release of glucocorticoids and has anti-inflammatory effects though melanocortin signaling, suggesting it might serve as a novel treatment for migraine prevention. Methods: This was a four center, two-arm, open-label study with 30 randomized subjects. All subjects met ICHD-IIR criteria for a diagnosis of chronic migraine and previously had failed at least two oral migraine preventatives as well as onabotulinumtoxinA. Following a 30-day baseline data collection period, subjects were randomized to receive either 40 IU or 80 IU of subcutaneous ACTH for 4 weeks. After the treatment phase subjects were followed for an additional 6 months. Results: When comparing baseline to treatment phase for all patients, we found a significant decrease in headache days (-2.2, p = .01) and migraine days (-2.2, p = .03). This reduction in headache days was greater for those receiving 80 IU than 40 IU, with those receiving 80 IU reporting a significant reduction in headache days (-2.6, p = .01) while the 40IU group had no significant change is headache days (-1.8, p = .21). A significant reduction in monthly headache days continued throughout the 6 month follow-up phase of the study F (7, 22) = .91, p = .03. Conclusions: Data from this pilot study suggest ACTH may be effective in reducing headache frequency in previously treatment-refractory patients with chronic migraine. Further investigation involving a larger subject population and double-blind methodology is needed to confirm this preliminary result.